Summary
Pax2 is a transcription factor with important functions during kidney development [1] [2] [3] . Ectopic expression of Pax2 in podocytes has been reported in various glomerular diseases [4] [5] [6] [7] , but the functional relevance remains unknown. We developed an inducible mouse model that allows activation of Pax2 specifically in podocytes. Persistent expression of Pax2 did not interfere with the initial differentiation of podocytes, but mice ectopically expressing PAX2 developed endstage renal failure soon after birth. Similarly, activation of PAX2 in healthy adult animals resulted in renal disease within 3 weeks after podocyte-specific induction of a deleter Cre. PAX2 activation caused repression of the podocyte key regulator molecule Wt1 and consequently a dramatic reduction of nephrin expression. Recruitment of the groucho-related protein TLE4 may be involved in converting Pax2 into a transcriptional repressor of Wt1. Finally, treatment of mice with an angiotensin-converting enzyme (ACE) inhibitor normalized renal function and induced upregulation of the important structural molecule nephrin via a Wt1-independent pathway. Our data demonstrate the functional significance of PAX2 reexpression in mature podocytes for the development of glomerular diseases and suggest that reactivation of PAX genes in terminally differentiated cells leads to a more dedifferentiated phenotype.
Results and Discussion
PAX2 encodes a transcriptional regulator with essential functions during kidney development [1, 2] . After completion of development, PAX2 expression in the kidney is restricted to a minority of epithelial cells [3] . Under pathological conditions, e.g., juvenile nephronophtisis [4] , cystic and hyperproliferative kidney epithelium [5] , focal segmental glomerulosclerosis [6] , and collapsing glomerulopathy, which occurs mostly as HIV-associated nephropathy (HIVAN) [7] , ectopic PAX2 expression in glomerular podocytes is a common finding. However, the functional consequence of PAX2 expression in glomerular diseases is not well understood. Thus, we directed the expression of this gene to the adult glomerular podocyte by means of a yeast artificial chromosome (YAC) covering the human WT1 locus ( Figure 1A ) [8] . The YAC was modified by inserting the mouse Pax2b cDNA preceded by an IRES signal into WT1 exon2. To avoid possible lethality due to ectopic Pax2 expression [9] and to permit a controlled activation of the transgene, we inserted a floxed b-geo cassette with a strong polyadenylation signal [10] into intron1 of the WT1 locus that acts as a marker and also as a STOP cassette, making expression of Pax2 Cre dependent. Heterozygous (Z/ Pax2) mice generated with this construct showed a normal lifespan and fertility. LacZ staining demonstrated the expression of the transgene in a WT1-specific pattern during kidney development and at high levels in mature glomerular podocytes ( Figure 1B and data not shown). To activate Pax2, we crossed Z/Pax2 mice with a Cre-deleter strain (Cre d ) [11] , which expresses the CRE recombinase ubiquitously. Immunofluorescent analysis in double heterozygous mice (Z/Pax2 +/2 ;Cre d ) confirmed the activation of Pax2 in developing glomeruli ( Figure 1C , part d). Ectopic expression of Pax2 under control of WT1 regulatory regions did not interfere with embryogenesis, and the embryonic kidney developed normally (data not shown). Electron microscopic analysis at embryonic day 16.5 (E16.5) revealed an identical glomerular development in double heterozygous mice and in controls ( Figure 1D , parts a and b). The more mature juxtamedullary glomeruli in double heterozygous mice possessed all glomerular cell types and were in the process of forming a normal filtration structure. They displayed groups of foot processes separated by a slit diaphragm, a glomerular basement membrane, and an endothelium with moderate fenestration. Perinatally, double transgenic mice developed quickly severe proteinuria and died within 5 days after birth, most probably due to renal failure. Histological analysis confirmed filtration defects with prominent protein casts in proximal tubules and collecting ducts ( Figure 1C , part e). Strikingly, glomeruli of double transgenic animals showed a collapse of the glomerular tuft ( Figure 1C , part f), reminiscent of collapsing glomerulopathy in humans. Electron microscopic analysis on days 1, 3, and 5 after birth revealed a lower degree of podocyte interdigitation in Figure 1 . Construct Design and Analysis of Mice Expressing Pax2 Ectopically in Glomerular Podocytes (A) Schematic drawing of the transgenic construct. A 480 kb YAC covering the human WT1 locus was used to provide WT1-specific regulatory elements. Pax2b cDNA preceded by an internal ribosomal entry site (IRES) and followed by a SV40 polyadenylation signal was inserted into exon2 of the WT1 locus. To provide control over transgene expression, a splice acceptor (SA)-IRES-b-galactosidase neomycin fusion gene (b-geo) followed by a polyadenylation signal and flanked by loxP sites was inserted into intron1. Ura3 and Leu2 represent selectable markers for yeast targeting. loxP sites are symbolized by black arrowheads. YAC transgenic animals were generated as described [28] . (B) Detection of b-galactosidase expression by lacZ staining of E18.5 mouse embryos [29] . Note that the transgene is expressed in a WT1-specific pattern with strong staining in developing glomeruli. [30] . Note the normal footprocess formation in double transgenic mice at E16. 5 (b) and the low number of foot processes of podocytes (P) and effacement of process interdigitations at P5. Scale bars equal 100 mm in (B) and (C) and 1 mm in (D). ) were generated by crossing Z/Pax2 transgenic animals with tamoxifen-inducible Cre-deleter mice [12] . Double transgenic offspring was identified by PCR by the following primers: YAC-
Tamoxifen induction was performed as described [12] . (A) Immunohistochemical staining with Pax2 antibodies reveals strong and specific expression in glomerular podocytes (b, c), whereas uninduced glomeruli are devoid of staining (a). Immunostaining was performed as described [31] with an anti-Pax2 antibody from rabbit (PRB-276P, Covance). (B) 3 weeks after induction, histological analysis revealed little changes with some shrinkage of the glomerular tuft (b). In contrast, kidneys 3 months after induction showed glomerular sclerosis and were fibrotic (c). (C) Sirius red staining was performed according to manufacturer's instruction. Note the increased collagen deposition (red) 3 months after Pax2 induction (b, c), but not after 3 weeks of induction (a). TUNEL analysis of kidneys from double transgenic mice (Z/Pax2;Cre Tx ) 3 weeks and 3 months after tamoxifen induction (arrows indicate glomeruli) was performed as described [32] . Massive apoptosis could be detected mainly in tubular cells but also in glomeruli 3 months after Pax2 induction (e, f). PCNA immunostaining (anti-PCNA antibody from mouse, sc-56, Santa Cruz Biotechnology) revealed proliferation of podocytes 3 months after activation of the transgene (h, i), whereas no PCNA staining could be detected 3 weeks after induction (g), suggesting that podocyte proliferation is a secondary event. Scale bars equal 100 mm. A) Urinary analysis demonstrates a dramatic increase in protein levels in double transgenic mice 3 weeks after tamoxifen induction (b) when compared to uninduced animals (a). Note that tamoxifen injection in the absence of the Cre Tx transgene had no effect on protein excretion (b). For measurement of urinary protein excretion, male mice were housed individually in metabolic cages (Techniplast, Italy), urine was collected over 24 hr, the volume was measured, and the protein concentration was determined with the Bio-Rad protein assay (Bio-Rad Laboratories, Germany). (B) Real-time RT-PCR analysis of molecular markers 3 weeks after tamoxifen induction in Z/Pax2;Cre Tx mice (white bars, n = 6) and controls (double transgenic mice injected with vehicle and single Z/Pax2 transgenic animals injected with tamoxifen, black bars, n = 12) was performed as described [31] . No statistically significant change could be detected for the proposed downstream targets of Pax2 Gdnf and Sfrp2. In contrast, double transgenic mice compared to wild-type. Pathological changes were most prominent in the oldest juxtamedullary glomeruli located in the deep cortex (see Figure S1 in the Supplemental Data available with this article online), although they were also apparent in younger glomerular populations. Podocyte foot processes with slit diaphragms were rare; almost the entire glomerular basement membrane surface was covered by broad cell processes with displaced cell junctions or by podocyte cell bodies ( Figure 1D, part c) . In these glomeruli, the low number of foot processes is indicative of dedifferentiation and effacement of process interdigitation. Midcortical glomeruli and several juxtamedullary glomeruli were less affected (data not shown). The low number of fully formed foot processes and slit diaphragms in these glomeruli may be the result of dedifferentiation and/or retarded differentiation. Interestingly, in several younger developing glomeruli of the outer cortex, filtration structures with rows of foot processes were present, further supporting the hypothesis that generally at least part of the foot processes first form and then dedifferentiate (data not shown). These results suggest that glomerular differentiation is normal during embryonic development, but at later stages dedifferentiation and pathological transformation occurs. Besides the kidney abnormalities described above, Z/Pax2 +/2 ;Cre d animals had smaller gonads and spleens and a reduced number of white blood cells, which may result from Pax2 expression under WT1 regulatory sequences ( Figure S2) .
To test the value of our model for functional studies, we examined whether ectopic expression of Pax2 would also cause glomerular disease when induced in adult podocytes. For this purpose, we employed a tamoxifen-inducible CRE line (Cre Tx ) that shows predominant expression in podocytes [12] . Pax2 expression could be detected as early as 1 week after tamoxifen injection in double transgenic mice and reached a plateau after 3 weeks (Figure 2A, parts b and c) . To estimate the degree of induction, double-immunofluorescent stainings for synaptopodin to identify the glomeruli and Pax2 were performed. Counting revealed that 95% 6 1.3% of the glomeruli expressed Pax2 after 3 weeks of induction, whereas no Pax2 expression in glomeruli could be detected in uninduced controls (six optical fields from three different animals each). Histological abnormalities became apparent as early as 3 weeks after induction and were characterized by mild shrinkage of the glomerular tuft and an increase of the glomerular space ( Figure 2B, part b) . By electron microscopy, podocytes often showed microvillous transformation at the apical cell membrane, indicative of initial stages of podocyte deterioration ( Figure S3A) . A large number of proximal tubules were also affected. In severely damaged tubules, inclusion bodies containing electron-dense and lamellated material were found, probably resulting from protein accumulation ( Figure S3B ) [13] . By 3 months, glomeruli became focal segmental sclerotic and tissues showed clear signs of fibrosis ( Figure 2B , part c), indicating that also focal segmental sclerosis, which is accompanied by glomerular Pax2 expression [6] in humans, might be due to prolonged Pax2 expression. Fibrosis was confirmed by collagen staining with Sirius Red (Waldeck GmbH, Mü nster, Germany), which was increased dramatically after 3 months ( Figure 2C , parts b and c) but not after 3 weeks ( Figure 2C, part a) .
Pax2 has been suggested to promote cellular proliferation [14] , and podocytes of patients with glomerular disease have been demonstrated to be positive for proliferation markers such as PCNA [6] . In addition, increased apoptosis in collapsing glomerulopathy [6] and focal segmental glomerulosclerosis [13] has been demonstrated. Analysis of our mouse model confirmed increased apoptosis predominantly in tubular cells, but also in the glomeruli ( Figure 2C , parts e and f) 3 months after tamoxifen injection. Increased proliferation of podocytes as assessed by immunostaining for PCNA occurred 3 months after activation of the transgene (Figure 2C , parts h and i). In contrast, no PCNA staining could be detected 3 weeks after induction, suggesting that podocyte proliferation is a secondary rather than a primary event ( Figure 2C , part g) in the development of glomerular diseases. These results were confirmed by immunostaining for Ki-67 as a marker for proliferation and cyclins D1/2 and E as indicators that the podocytes reenter the cell cycle (data not shown). Proliferating cells in the glomerulus were identified as podocytes by double-staining with cyclin E and synaptopodin ( Figure S4 ). The histological findings were confirmed on a functional level. Z/Pax2;Cre Tx mice developed 3 weeks after tamoxifen injection a significant proteinuria as a marker for disturbed kidney function when compared to Z/ Pax2;Cre Tx animals injected with vehicle. A nonspecific effect of tamoxifen administration could be excluded since single Z/Pax2 transgenic mice injected in parallel with the same dose of tamoxifen did not develop proteinurea ( Figure 3A) . [33] . Cotransfection of TLE4 (Grg4) [3] suppressed Pax2b-specific activation of the Wt1 promoter in a dose-dependent fashion. pGl2basic served as an empty vector control. Cell culture, transient transfections, and reporter assays were performed as described [31] . (For experimental details, see Supplemental Experimental Procedures.)
To understand the molecular pathway leading to glomerular disease, we next analyzed the expression of Gdnf and the frizzled related protein Sfrp2, two genes that have been proposed to be transcriptional targets of Pax2 [15, 16] . Real-time RT-PCR analysis 3 weeks after tamoxifen injection detected no statistically significant difference between induced animals and controls ( Figure 3B ). As controls for all real-time RT-PCR analysis, double-transgenic mice injected with vehicle and single Z/Pax2 transgenic animals injected in parallel with tamoxifen were used. Since no significant differences between these two control groups could be detected for any of the investigated parameters, they were pooled for the final statistical comparison to the induced animals. The lack of upregulation of Gdnf and Sfrp2 in the induced animals suggests that at least in podocytes, expression of Pax2 is not sufficient to activate these genes ( Figure 3B ). We next addressed whether the expression of podocyte-specific markers was altered after Pax2 induction. Wt1 is a transcription factor regulating several key proteins of the podocyte including nephrin [17] and podocalyxin [18] , and reduced levels of Wt1 have been shown to cause glomerular diseases [8] . Strikingly, RT-PCR analyses and immunohistochemistry demonstrated a dramatic reduction of both Wt1 and nephrin in tamoxifen-induced mice ( Figures  3B and 3C ), whereas expressions of podocalyxin (Figure 3B ) and synaptopodin ( Figure 3C) were not significantly changed, pointing toward a direct regulation of Wt1 and nephrin in our model instead of being solely a reflection of glomerular damage. Cotransfection assays in HeLa cells showed that Pax2 weakly activates rather than represses a nephrin promoter construct [19] , suggesting that repression of nephrin is not a direct effect of the upregulation of Pax2. Given the phenotype of nephrin mutations in man and mouse [20, 21] , we propose that the severe reduction in the expression of this gene in our mouse model contributes significantly to the observed defects, thus once again underlining its importance for the formation of the filtration barrier. Furthermore, expression of the At1 receptor, which is deregulated in human kidney diseases [22] , was reduced in tamoxifen-induced mice. Since in a cell line with inducible WT1 expression, mRNA for the AT1 receptor was increased by a factor of 2.0 6 0.3 (n = 5, p < 0.05) upon WT1 induction (data not shown), it is likely that also this molecule directly depends on Wt1, pointing again at a role of Wt1 as a key regulator for glomerular disease.
Earlier publications have described Wt1 as a direct target of the transcriptional activator Pax2 [23] in different nonkidney cell lines, and as such we could have expected an increase in Wt1 rather than the observed dramatic reduction in animals ectopically expressing Pax2. Several Pax proteins are able to interact with groucho (TLE) family members [3, 24] , which convert these proteins from transcriptional activators to repressors. In the kidney, TLE4 has been described to be expressed specifically within differentiated podocytes [24] , and TLE4 mRNA levels did not differ between tamoxifen-induced animals and controls (data not shown).
To test whether TLE4 can suppress Pax2-dependent activation of Wt1, we performed cotransfection experiments with the Wt1 promoter and a Pax2 expression construct in the presence or absence of TLE4 in HeLa cells. As expected from the literature [23] , cotransfection of Pax2 with the Wt1 reporter construct led to moderate activation of the Wt1 promoter. This activation could be suppressed in a dose-dependent fashion in the presence of TLE4 ( Figure 3C ). These in vitro data might at least in part explain the dramatic downregulation of the Wt1 gene in our tamoxifen-induced mouse model in vivo. This regulatory pathway might be also important for human glomerular diseases, where Pax2 expression has been described in adult podocytes [6] .
Glomerular diseases in human patients are typically treated with drugs interfering with the renin-angiotensin system [25] . We therefore tested whether our mouse model would respond to the angiotensin converting enzyme (ACE) inhibitor enalapril at a dose (3 mg/kg/day) that has no significant effect on systemic blood pressure [26] , although we can not exclude that this dose has a blood pressure lowering effect in our diseased mice. We followed protein excretion as a diagnostic marker for a total of 3 weeks. Untreated mice suffered from severe proteinuria and only 5 out of 23 mice survived during the observation period. In contrast, enalapril treatment resulted in a significant reduction of excreted protein levels ( Figure 4A ) and a dramatically increased survival (9 out of 11). These improvements are unlikely to be due to a simple stabilization of the vascular component of the glomerulus, since VEGF-A and angiopoietin 1 levels were not significantly different in treated versus untreated animals (data not shown). Angiotensin II in the mouse acts primarily through the angiotensin receptor At1a, and we hypothesized that enalapril treatment may result in a molecular response in the expression of the receptor. Indeed, real-time RT-PCR analysis demonstrated a significant increase of At1a mRNA, probably reflecting a physiological feedback mechanism. Also, nephrin expression was higher in enalapril-treated animals when compared to controls, as it has been already reported for other models of glomerular disease treated with ACE inhibitors [27] , whereas Wt1 showed no significant change ( Figure 4C) . Surprisingly, Pax2 expression was increased in enalapril-treated animals when compared to controls ( Figure 4C ). This enhanced expression could be localized by immunohistochemistry to glomerular, tubular, and collecting duct cells (data not shown) and might at least in part be due to proliferation of these cells already after 3 weeks of tamoxifen induction combined with enalapril treatment ( Figure 4B ). Taken together, these data demonstrate that ACE inhibitors exhibit a curative effect also in our mouse model, which at least in part could be attributed to partial normalization of the expression of Wt1-dependent genes, although we cannot exclude that other yet unidentified mechanisms might play a role.
In summary, we have generated a unique genetically inducible model for renal disease, which is informative for successive events and molecular alterations in the development of glomerular disease. Our data provide evidence that ectopic expression of PAX2 in glomerular podocytes represents a major factor for the development of glomerular disease. In contrast to the normal developmental regulation, the activation of Pax2 in mature podocytes seems to repress Wt1 and consequently leads to the repression of the crucial structural protein nephrin. Molecular analysis of ACE inhibitortreated animals shows that expression of podocytespecific genes such as nephrin can be increased through mechanisms different from the developmental regulation.
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